Literature DB >> 15564135

Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.

Tanya J Shaw1, Mary K Senterman, Kerri Dawson, Colleen A Crane, Barbara C Vanderhyden.   

Abstract

Improvement of ovarian cancer patient outcome requires well-characterized animal models in which to evaluate novel therapeutics. Xenograft models are frequently used, but with little discussion of disease histology. The objectives of this study were to inject 11 ovarian cancer cell lines intraperitoneally (ip), and a subset intrabursally (ib; orthotopic), into nude mice and to analyze the resulting pathologies. Eight of 11 lines injected ip formed tumors within 3 months at variable rates with the following histological subtype distribution: one endometrioid, one serous, one clear cell, and five undifferentiated. Only mice injected with A2780-cp cells presented with ovarian-specific metastases (11 of 88), and the survival time of these animals was significantly shorter, which may be attributed to the higher proliferation rate as determined by Ki67 positivity. Additional analysis of the influence of the ovarian microenvironment on cell characteristics was conducted with ib injection of two cell lines (OVCA 429 and ES-2). The site of injection did not affect the tumor histology, the effect on proliferation was cell-type dependent, and the tumor take rate (cell survival) was negatively affected for OVCA 429 cells. The animal models described herein represent histologically distinct models of both early and late stage ovarian cancer useful for evaluation of therapeutics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564135     DOI: 10.1016/j.ymthe.2004.08.013

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  136 in total

1.  Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.

Authors:  Sara Previdi; Anastasia Malek; Veronica Albertini; Cristina Riva; Carlo Capella; Massimo Broggini; Giuseppina M Carbone; Jurgen Rohr; Carlo V Catapano
Journal:  Gynecol Oncol       Date:  2010-05-08       Impact factor: 5.482

2.  Targeting c-MYC in Platinum-Resistant Ovarian Cancer.

Authors:  Jeyshka M Reyes-González; Guillermo N Armaiz-Peña; Lingegowda S Mangala; Fatma Valiyeva; Cristina Ivan; Sunila Pradeep; Ileabett M Echevarría-Vargas; Adrian Rivera-Reyes; Anil K Sood; Pablo E Vivas-Mejía
Journal:  Mol Cancer Ther       Date:  2015-07-30       Impact factor: 6.261

3.  High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro.

Authors:  Fan Wang; Jeremy T-H Chang; Chester Jingshiu Kao; R Stephanie Huang
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

4.  Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib.

Authors:  Sarah E Bohndiek; Laura S Sasportas; Steven Machtaler; Jesse V Jokerst; Sharon Hori; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2015-08-27       Impact factor: 10.057

5.  Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.

Authors:  Alice Chanakira; Pamela R Westmark; Irene M Ong; John P Sheehan
Journal:  Gynecol Oncol       Date:  2017-01-29       Impact factor: 5.482

6.  Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.

Authors:  Amelie M Lutz; Sunitha V Bachawal; Charles W Drescher; Marybeth A Pysz; Jürgen K Willmann; Sanjiv Sam Gambhir
Journal:  Clin Cancer Res       Date:  2014-01-03       Impact factor: 12.531

Review 7.  The mammalian ovary from genesis to revelation.

Authors:  Mark A Edson; Ankur K Nagaraja; Martin M Matzuk
Journal:  Endocr Rev       Date:  2009-09-23       Impact factor: 19.871

8.  Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion.

Authors:  Trevor G Shepherd; Michelle L Mujoomdar; Mark W Nachtigal
Journal:  J Ovarian Res       Date:  2010-02-26       Impact factor: 4.234

9.  Targeted delivery of platinum-taxane combination therapy in ovarian cancer.

Authors:  Swapnil S Desale; Kruti S Soni; Svetlana Romanova; Samuel M Cohen; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-09-14       Impact factor: 9.776

10.  Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.

Authors:  Hyunah Cho; Tsz Chung Lai; Glen S Kwon
Journal:  J Control Release       Date:  2012-12-13       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.